Ivacaftor/lumacaftor attenuated IL-18 secretion through drug-naïve CF monocytes from homozygous F508del patients but not IL-1β, while ivacaftor/tezacaftor reduced both cytokines levels. This evidence concerns the gene IL18 and cystic fibrosis.